Welcome to our dedicated page for LHCG news (Ticker: LHCG), a resource for investors and traders seeking the latest updates and insights on LHCG stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LHCG's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LHCG's position in the market.
LHC Group, Inc. (NASDAQ: LHCG) has scheduled its earnings release for the second quarter ending June 30, 2021, after market close on August 4, 2021. The company will hold a conference call the following day, August 5, 2021, at 9:00 a.m. Eastern Time. Interested parties can join via a toll-free number or through a webcast available on the company's website. LHC Group provides in-home healthcare services, aiming to reach a significant portion of the U.S. elderly population.
Provident Healthcare Partners advised Heart 'n Home Hospice in its acquisition by LHC Group (NASDAQ: LHCG), marking LHC Group's entry into Oregon's hospice care market and expansion in Idaho. Heart 'n Home, a respected provider of hospice services in Oregon and Idaho, operates 10 locations. The transaction aligns with LHC Group's strategy to offer in-home healthcare solutions. The terms of the deal remain undisclosed, reflecting a growing investor interest in quality hospice assets due to demographic trends.
LHC Group announced agreements to acquire three home health, hospice, and palliative care providers in Virginia, Indiana, and Arkansas, with an expected annual revenue increase of approximately $8 million. Additionally, the company completed purchases in Idaho, Oregon, Arizona, and Texas, with projected revenues of $20 million and $23 million from two of these acquisitions. The finalized transactions are anticipated to close by August 1, 2021, and will not materially impact diluted earnings per share for 2021.
LHC Group (NASDAQ: LHCG) announced a definitive agreement to purchase Heart of Hospice, expanding its presence in five states, including Arkansas and Louisiana. This acquisition includes 16 hospice agencies, projected to generate annualized revenue of approximately $92.5 million. The deal is expected to close in Q3 2021 and will not materially impact 2021 diluted earnings per share. As a leader in home healthcare services, LHC Group serves 60% of the U.S. population aged 65 and older, collaborating with nearly 400 hospitals and health systems to deliver effective care.
LHC Group, Inc. (NASDAQ: LHCG) is set to present at William Blair's 41st Annual Growth Stock Conference on June 1, 2021, at 3:00 p.m. Eastern time, and at the Jefferies Healthcare Conference on June 3, 2021, at 10:30 a.m. Eastern time. Both events will be accessible via live webcasts. LHC Group, a provider of in-home healthcare services, operates in 35 states and the District of Columbia, serving 60% of the U.S. population aged 65 and older. Replays of the presentations will be available on their website for 30 days following the events.
LHC Group (NASDAQ: LHCG) announced its agreement to acquire Heart 'n Home Hospice based in Fruitland, Idaho. This acquisition extends LHC Group's hospice services into Oregon and enhances its presence in Idaho with three hospice providers totaling six locations in Idaho and four in Oregon. The deal, expected to close by July 1, 2021, is projected to generate annualized revenue of approximately $20 million without significantly impacting 2021 diluted earnings per share. The company emphasizes the growing need for quality hospice care in the region.
LHC Group (NASDAQ: LHCG) announced its agreement to purchase two Casa de la Luz hospice locations in Tucson, Arizona, set to close on July 1, 2021. This acquisition aims to enhance hospice services in the Tucson region and aligns with LHC Group's growth strategy. The expected annual revenue from this acquisition is approximately $23 million, with no material impact on 2021 diluted earnings per share. LHC Group currently operates over 120 hospice facilities nationwide, dedicated to providing compassionate end-of-life care.
LHC Group (NASDAQ: LHCG) announced its participation in the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021. The virtual fireside chat is set to start at 9:10 a.m. Eastern time, with a live webcast available for attendees. Listeners can access the webcast through the Investor Relations section of LHC Group's website.
LHC Group is a national provider of in-home healthcare services, reaching 60% of the U.S. population aged 65 and older.
LHC Group (NASDAQ: LHCG) will present at the BofA Securities 2021 Healthcare Conference on May 11, 2021, starting at 2:45 a.m. Eastern time. Interested parties can access a live webcast via the Company’s Investor Relations page. Replays will be available for 30 days on the website. LHC Group specializes in in-home healthcare services across 35 states, serving a significant portion of the aging population in the U.S.
LHC Group (NASDAQ: LHCG) reported its financial results for Q1 2021, showing a 2.3% increase in net service revenue to $524.8 million. Net income soared 57.4% to $34.7 million, with earnings per share reaching $1.10. Adjusted net income jumped 86.7% and EBITDA grew 48.3% to $49.4 million. The company raised its full-year revenue guidance to $2.215 billion to $2.265 billion. Despite a 0.4% decline in home health admissions, hospice admissions rose 7.6%.
FAQ
What is the market cap of LHCG (LHCG)?
